MedTrace Logo

A Study to Compare the Pharmacokinetic Profiles of DW224aa and DW224a

NCT01341249 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2011-07-18

No results posted yet for this study

Summary

The purpose of this study is to compare and explore pharmacokinetics of zabofloxacin, the main component of DW224aa(Test drug) and DW224a(Reference drug).

Conditions

  • Healthy

Interventions

DRUG

Experimental DW224aa

DW224aa tablet, single dose

DRUG

Experimental DW224a

DW224a capsule, single dose

Sponsors & Collaborators

  • Dong Wha Pharmaceutical Co. Ltd.

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Kyung Sang Yu, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341249 on ClinicalTrials.gov